Quince completes Phase 3 NEAT enrollment with 105 patients; topline results Q1 2026

Quince Therapeutics, Inc.

Enrolled 105 participants total; 83 in primary analysis (ages 6-9), 22 aged 10+.
Powering at ~90% for primary endpoint; trial under FDA Special Protocol Assessment.
Topline results expected Q1 2026; NDA submission planned H2 2026 if positive.
All enrolled participants have elected to transition to open-label extension study.
FDA Fast Track designation and SPA agreement in place for eDSP in Ataxia-Telangiectasia.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.